2023-507075-22-00
Recruiting
Phase 1
Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients
Eurofins Optimed, Perha Pharmaceuticals1 site in 1 country120 target enrollmentDecember 13, 2023
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Eurofins Optimed, Perha Pharmaceuticals
- Enrollment
- 120
- Locations
- 1
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Alize FARGIER
Scientific
Eurofins Optimed
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.2023-509961-19-00Novo Nordisk A/S42
Completed
Phase 1
Study to evaluate the effects of new drug of diabetes mellitus in healthy volunteers.CTRI/2016/01/006507Cadila Pharmaceuticals Ltd36
Recruiting
Phase 1
Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patientsA Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s diseaseTherapeutic area: Diseases [C] - Nervous System Diseases [C10]CTIS2023-507075-22-00Eurofins Optimed120
Active, not recruiting
Not Applicable
Pharmacokinetics, efficacy, tolerability and safety evaluation of the therapy with subcutaneous immunoglobulin in the treatment of hypo or agammaglobulinaemic patients. Open label phase II/III study - NDHypogammaglobulinaemia or agammaglobulinaemiaMedDRA version: 9.1Level: LLTClassification code 10060384MedDRA version: 9.1Level: LLTClassification code 10001471EUCTR2010-020167-20-ITKEDRIO
Unknown
Phase 1
Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161Solid TumorC-Met Mutation-Related TumorsNCT04228406Fujian Cosunter Pharmaceutical Co. Ltd62